Genomic profiling for cholangiocarcinoma and other cancers demonstrates significant evidence-based benefits, but faces practical hurdles.
Over the last decade, medical research has led to significant progress in the diagnosis and treatment of perihilar cholangiocarcinoma.
Disease progression has a major impact on outcomes in patients with intrahepatic cholangiocarcinoma and many factors influence recurrence-free survival, studies have found.
Many are heralding radiomics as the “next big thing” that will revolutionize medicine. We examine this claim, particularly when it comes to cholangiocarcinoma treatment.
Researchers explain the specific challenges of diagnosing and managing iCCA, and why a multidisciplinary approach works best.
We explore the risk factors associated with the various subtypes of cholangiocarcinoma and discuss their reliability.
Various medical imaging tools can play key roles in the detection, diagnosis, and monitoring of cholangiocarcinoma.
We explore the multifaceted role of endoscopy in both the diagnosis and treatment of cholangiocarcinoma, as well as future considerations.
We explore the importance of correct and timely diagnosis of cholangiocarcinoma (CCA), which can be divided into iCCA, pCCA, and dCCA.
We examine and compare the latest guidelines on cholangiocarcinoma treatment, looking at both resectable and unresectable disease.